Rescue therapy with upadacitinib in severe Crohn’s disease
Miłosz Caban, Adam Fabisiak, Patrycja Dudek, Ewa Małecka-Wojciesko · 2026
Read Rescue therapy with upadacitinib in severe Crohn’s disease by Miłosz Caban, Adam Fabisiak, Patrycja Dudek, Ewa Małecka-Wojciesko (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13386257.txt.
Description
Miłosz Caban, Adam Fabisiak, Patrycja Dudek and Ewa Małecka-Wojciesko review rescue therapy with upadacitinib in severe Crohn's disease, in this 2026 Europe PMC paper. Crohn's causes chronic inflammation through the gut wall, and at least a fifth of patients face a severe flare needing hospital care. First-line care is intravenous steroids.
If patients do not improve within a week, treatment must step up before surgery is considered. Biologics such as infliximab and adalimumab can serve as rescue therapy, with infliximab often favored for its dosing and speed. Colectomy remains the fallback for toxic megacolon or resistant colitis. Data on rescue options are limited and mixed, which frames the case for newer drugs.
Catalog record
| CREATOR | Miłosz Caban, Adam Fabisiak, Patrycja Dudek, Ewa Małecka-Wojciesko |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |